Iki, Masayuki http://orcid.org/0000-0003-2128-5255
Fujimori, Kenji
Nakatoh, Shinichi
Tamaki, Junko
Ishii, Shigeyuki
Okimoto, Nobukazu
Imano, Hironori
Ogawa, Sumito
Funding for this research was provided by:
Taiju Life Social Welfare Foundation (Medical Research Grant 2019)
Japan Osteoporosis Foundation (Grant for Bone Research 2019)
Pfizer Foundation (Health Research Grant 2019)
Article History
Received: 25 May 2023
Accepted: 15 January 2024
First Online: 24 January 2024
Declarations
:
: The study protocol was approved by the Ethics Committee of Kindai University Faculty of Medicine (Approval Number: 31–065).
: We analyzed data provided by the Ministry of Health, Labour and Welfare which were completely anonymous. Therefore, informed consent from each patient was not required.
: Publication of the present manuscript was approved by the Ministry of Health, Labour and Welfare and all authors.
: Nobukazu Okimoto has received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd. and Teijin Pharma Ltd., and payments for lectures, including speakers’ bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd., Amgen K.K., Chugai Pharmaceutical Co., Daiichi-Sankyo Co., Ltd., Eli Lilly Japan, and Teijin Pharma Ltd. Shinichi Nakatoh has received payments for lectures, including speakers’ bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd., Amgen K.K., and Daiichi-Sankyo Co., Ltd. Shigeyuki Ishii has received honorarium from Teijin Pharma Ltd., and has written manuscripts for Asahi Kasei Pharma Ltd. Masayuki Iki, Kenji Fujimori, Junko Tamaki, and Sumito Ogawa declare that they have no conflict of interest.
: The present study is not registered.